Succinate Salt Form of Benzimidazole Amine for Stable Solid Formulation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, such as sulphate salts, face stability issues during drying and polymorphic form conversion, making them unsuitable for solid formulations, and other salts have hygroscopicity or toxicity concerns.

Innovation Solution

Development of succinate salts with stable polymorphic forms that are non-hygroscopic and obtainable through a one-pot salt formation/crystallization process, ensuring high crystallinity and stability, suitable for solid formulations.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If free base forms or salt forms other than succinate salts are used, then the compound can be formulated, but the stability and solubility profile are insufficient for optimal pharmaceutical use

Engineering Contradiction:
ImprovestabilityVSAvoidsolubility profile
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies parameter changes by selecting succinate salt specifically, which alters the chemical and physical parameters of the compound. The succinate salt form provides optimal balance between stability and solubility compared to other salt forms or free base, demonstrating how changing the salt parameter resolves the contradiction between stability and solubility profile

Inventive Principle:
Principle #35Parameter changes

2Productivity

If conventional synthesis methods are used, then the compound can be produced, but the process is time-consuming and yields are not optimal

Engineering Contradiction:
ImproveyieldVSAvoidsynthesis time
Core Design Contradiction:
ProductivityVSLoss of time

Solution Approach 1:

The patent employs preliminary action by performing protective group removal and salt formation in a one-pot process without isolation of intermediates. This approach eliminates time-consuming isolation and purification steps while maintaining high yields, directly addressing the contradiction between productivity and synthesis time

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent merges multiple synthetic steps (protective group removal and salt formation) into a single operational step. By combining these steps and avoiding intermediate isolation, the process achieves both high yield and reduced synthesis time, resolving the contradiction between productivity and time loss

Inventive Principle:
Principle #5Merging (Combining)

3Manufacturing precision

If multiple isolation and purification steps are performed, then the compound can be purified, but the process becomes complex and time-consuming

Engineering Contradiction:
ImprovepurificationVSAvoidprocess complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent extracts only the essential purification step by performing salt formation that simultaneously achieves purification. The succinate salt formation selectively precipitates or crystallizes the desired product while leaving impurities in solution, eliminating the need for multiple isolation and purification steps while maintaining manufacturing precision

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses salt formation as an intermediary process that serves dual purposes: purification and product isolation. The succinate salt acts as an intermediary form that facilitates purification in a single step, reducing process complexity while maintaining the required manufacturing precision

Inventive Principle:
Principle #24Intermediary (Mediator)

Data Source

PatentEP4222144B1Succinate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same
Publication Date: 2026.05.20 ALZPROTECT
  • EP4222144B1 patent drawingFigure 1
  • EP4222144B1 patent drawingFigure 2
  • EP4222144B1 patent drawingFigure 3

AI summary

The present invention relates to succinate salts of N-(3-(4-(3- (diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharmaceutically acceptable solvates thereof, preparation thereof, pharmaceutical compositions containing them and use of the same in the treatment and/or prevention of neurodegenerative diseases.